King's College London

Research portal

Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer

Research output: Contribution to journalArticle

Standard

Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. / Vasiljević, N; Ahmad, A S; Beesley, C; Thorat, M A; Fisher, G; Berney, D M; Moller, Henrik; Yu, Y; Lu, Y-J; Cuzick, J; Foster, C S; Lorincz, A T.

In: PROSTATE CANCER AND PROSTATIC DISEASES, Vol. 16, 2013, p. 35–40.

Research output: Contribution to journalArticle

Harvard

Vasiljević, N, Ahmad, AS, Beesley, C, Thorat, MA, Fisher, G, Berney, DM, Moller, H, Yu, Y, Lu, Y-J, Cuzick, J, Foster, CS & Lorincz, AT 2013, 'Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer', PROSTATE CANCER AND PROSTATIC DISEASES, vol. 16, pp. 35–40. https://doi.org/10.1038/pcan.2012.47

APA

Vasiljević, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D. M., Moller, H., Yu, Y., Lu, Y-J., Cuzick, J., Foster, C. S., & Lorincz, A. T. (2013). Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES, 16, 35–40. https://doi.org/10.1038/pcan.2012.47

Vancouver

Vasiljević N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM et al. Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2013;16:35–40. https://doi.org/10.1038/pcan.2012.47

Author

Vasiljević, N ; Ahmad, A S ; Beesley, C ; Thorat, M A ; Fisher, G ; Berney, D M ; Moller, Henrik ; Yu, Y ; Lu, Y-J ; Cuzick, J ; Foster, C S ; Lorincz, A T. / Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. In: PROSTATE CANCER AND PROSTATIC DISEASES. 2013 ; Vol. 16. pp. 35–40.

Bibtex Download

@article{6e1592a5dc954f6197f4dac1a9c3684f,
title = "Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer",
abstract = "Background: Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome. In contrast, the protein is not expressed in PCas of low malignant potential. To gain insight into the mechanism regulating its expression, we tested the hypothesis that differential methylation of CpG islands within HSPB1 controls transcription and subsequent translation of the gene.Methods: We studied prostate epithelial cell lines and tissue biopsies, including 59 BPH and 415 PCas, of which 367 were a cohort of men with up to 20 years of follow-up. Methylation across the gene (DNA methylation (DNAme)) was assayed by pyrosequencing. Hsp-27 expression was assessed by western blot and immunohistochemistry.Results: In cancer tissues, methylation increased in a 3′ direction (P<0.0001) whereas in benign hyperplasia methylation was constantly below 5%, a cutoff giving a specificity of 100% and sensitivity of 50%. Although methylation of the promoter region was significantly discriminating between benign and malignant prostatic epithelia, it compared poorly with methylation of the first intron. The prognostic value of HSPB1 DNAme was confirmed by both univariate (hazard ratio 1.77 per 50% increment, P=0.02) and multivariate models. Interaction between HSPB1 methylation and Gleason score revealed high DNAme to be a reliable prognostic marker of poor outcome in men with low Gleason score (P=0.014).Conclusions: Our data indicate CpG methylation of the first HSPB1 intron to be an important biomarker that identifies aggressive PCas otherwise regarded as low risk by current clinical criteria but that, biologically, require immediate active management.",
author = "N Vasiljevi{\'c} and Ahmad, {A S} and C Beesley and Thorat, {M A} and G Fisher and Berney, {D M} and Henrik Moller and Y Yu and Y-J Lu and J Cuzick and Foster, {C S} and Lorincz, {A T}",
year = "2013",
doi = "10.1038/pcan.2012.47",
language = "English",
volume = "16",
pages = "35–40",
journal = "PROSTATE CANCER AND PROSTATIC DISEASES",
issn = "1365-7852",
publisher = "Nature Publishing Group",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer

AU - Vasiljević, N

AU - Ahmad, A S

AU - Beesley, C

AU - Thorat, M A

AU - Fisher, G

AU - Berney, D M

AU - Moller, Henrik

AU - Yu, Y

AU - Lu, Y-J

AU - Cuzick, J

AU - Foster, C S

AU - Lorincz, A T

PY - 2013

Y1 - 2013

N2 - Background: Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome. In contrast, the protein is not expressed in PCas of low malignant potential. To gain insight into the mechanism regulating its expression, we tested the hypothesis that differential methylation of CpG islands within HSPB1 controls transcription and subsequent translation of the gene.Methods: We studied prostate epithelial cell lines and tissue biopsies, including 59 BPH and 415 PCas, of which 367 were a cohort of men with up to 20 years of follow-up. Methylation across the gene (DNA methylation (DNAme)) was assayed by pyrosequencing. Hsp-27 expression was assessed by western blot and immunohistochemistry.Results: In cancer tissues, methylation increased in a 3′ direction (P<0.0001) whereas in benign hyperplasia methylation was constantly below 5%, a cutoff giving a specificity of 100% and sensitivity of 50%. Although methylation of the promoter region was significantly discriminating between benign and malignant prostatic epithelia, it compared poorly with methylation of the first intron. The prognostic value of HSPB1 DNAme was confirmed by both univariate (hazard ratio 1.77 per 50% increment, P=0.02) and multivariate models. Interaction between HSPB1 methylation and Gleason score revealed high DNAme to be a reliable prognostic marker of poor outcome in men with low Gleason score (P=0.014).Conclusions: Our data indicate CpG methylation of the first HSPB1 intron to be an important biomarker that identifies aggressive PCas otherwise regarded as low risk by current clinical criteria but that, biologically, require immediate active management.

AB - Background: Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome. In contrast, the protein is not expressed in PCas of low malignant potential. To gain insight into the mechanism regulating its expression, we tested the hypothesis that differential methylation of CpG islands within HSPB1 controls transcription and subsequent translation of the gene.Methods: We studied prostate epithelial cell lines and tissue biopsies, including 59 BPH and 415 PCas, of which 367 were a cohort of men with up to 20 years of follow-up. Methylation across the gene (DNA methylation (DNAme)) was assayed by pyrosequencing. Hsp-27 expression was assessed by western blot and immunohistochemistry.Results: In cancer tissues, methylation increased in a 3′ direction (P<0.0001) whereas in benign hyperplasia methylation was constantly below 5%, a cutoff giving a specificity of 100% and sensitivity of 50%. Although methylation of the promoter region was significantly discriminating between benign and malignant prostatic epithelia, it compared poorly with methylation of the first intron. The prognostic value of HSPB1 DNAme was confirmed by both univariate (hazard ratio 1.77 per 50% increment, P=0.02) and multivariate models. Interaction between HSPB1 methylation and Gleason score revealed high DNAme to be a reliable prognostic marker of poor outcome in men with low Gleason score (P=0.014).Conclusions: Our data indicate CpG methylation of the first HSPB1 intron to be an important biomarker that identifies aggressive PCas otherwise regarded as low risk by current clinical criteria but that, biologically, require immediate active management.

U2 - 10.1038/pcan.2012.47

DO - 10.1038/pcan.2012.47

M3 - Article

C2 - 23165430

VL - 16

SP - 35

EP - 40

JO - PROSTATE CANCER AND PROSTATIC DISEASES

JF - PROSTATE CANCER AND PROSTATIC DISEASES

SN - 1365-7852

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454